Topics
- COVID-19 (101)
- Advertising (74)
- COVID-19 vaccines (62)
- Prescription medicines (29)
- Medical devices (20)
- Regulatory compliance (18)
- Alert/Advisory (14)
- Medicines safety (9)
- In Vitro Diagnostic medical devices (IVDs) (6)
- Manufacturing (6)
- Disinfectants/Sterilants (5)
- Medicines (5)
- OTC medicines (3)
- Labelling and packaging (2)
- Shortages (2)
- Australian Register of Therapeutic Goods (ARTG) (1)
- Biologicals (1)
- Medicinal cannabis hub (1)
- Safety (1)
- Scheduling (1)
- Unapproved therapeutic goods (1)
Collection content
293 result(s) found, displaying 81 to 90
- Media releasesTGA provisionally approves Novavax (Biocelect Pty Ltd's) COVID-19 vaccine NUVAXOVIDOn 19 January 2022 the TGA granted provisional approval to Biocelect Pty Ltd (on behalf of Novavax Inc) in relation to the COVID-19 vaccine, NVX-CoV2373, for individuals aged 18 years and over.
- COVID-19 vaccine safety reportsCOVID-19 vaccine weekly safety report - 20-01-2022TGA's safety monitoring of COVID-19 vaccines.
- Media releasesTGA recognises the Gamaleya Institute vaccine (Sputnik V, Russian Federation) for international travel to AustraliaThe TGA determined that the two dose course of the Gamaleya Institute vaccine (Sputnik V, Russian Federation) would be 'recognised' for the purpose of establishing a traveller's vaccination status.
- Media releasesEzy Company Pty Ltd fined $26,640 for alleged unlawful importation of COVID-19 rapid antigen tests and nicotine vaping productsThe TGA has issued an infringement notice, totalling $26,640, to Ezy Company Pty Ltd for alleged unlawful importation of COVID-19 rapid antigen tests and nicotine vaping products in breach of the Therapeutic Goods Act 1989.
- COVID-19 vaccine safety reportsCOVID-19 vaccine weekly safety report - 13-01-2022Information about the TGA's safety monitoring of COVID-19 vaccines.
- COVID-19 vaccine safety reportsCOVID-19 vaccine weekly safety report - 06-01-2022Information about the TGA's safety monitoring of COVID-19 vaccines.
- Media releasesTGA grants provisional determination to AstraZeneca Pty Ltd for COVID-19 prophylaxis and treatment, tixagevimab and cilgavimab (EVUSHELD)On 4 January 2022 the TGA granted a further provisional determination to AstraZeneca Pty Ltd in relation to the COVID-19 treatment tixagevimab and cilgavimab (EVUSHELD).
- COVID-19 vaccine safety reportsCOVID-19 vaccine weekly safety report - 16-12-2021Information about the TGA's safety monitoring of COVID-19 vaccines.
- Media releasesTGA warns about imports of ivermectinTGA has tested a number of imported products labelled as ivermectin and found that they are counterfeit
- NewsRegulation of Personal Protective Equipment and COVID-19An overview of the regulation of Personal Protective Equipment (PPE) in Australia, including face masks, gowns and gloves